FDA.reportPublic FDA data

atrasentan 0.75 MG Oral Tablet

RxCUI
2710454
RxNorm name
atrasentan 0.75 MG Oral Tablet
Display name
atrasentan 0.75 MG Oral Tablet
Full name
atrasentan 0.75 MG Oral Tablet
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:10

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
VANRAFIAATRASENTANNovartis Pharmaceuticals Corporation9a7e7f85-bfd0-44a0-beda-3bcfa8215c642026-06-12Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2710454

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
9a7e7f85-bfd0-44a0-beda-3bcfa8215c64atrasentan 0.75 MG Oral Tablet [PSN] · atrasentan 0.75 MG Oral Tablet [SCD] · atrasentan 0.75 MG (equivalent to atrasentan hydrochloride 0.803 MG) Oral Tablet [SY]32These highlights do not include all the information needed to use VANRAFIA safely and effectively. See full prescribing information for VANRAFIA. VANRAFIA ™ (atrasentan) tablets, for oral use Initial U.S. Approval: 202520250606